Goodwill in USD of Oncotelic Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
Summary
Oncotelic Therapeutics, Inc. quarterly Goodwill history and change rate from Q1 2019 to Q3 2025.
  • Oncotelic Therapeutics, Inc. Goodwill for the quarter ending 30 Sep 2025 was $2.79M, unchanged year-over-year.
Goodwill, Quarterly (USD)
Goodwill, YoY Quarterly Change (%)

Oncotelic Therapeutics, Inc. Quarterly Goodwill (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $2.79M $0 0% 30 Sep 2025 10-Q 17 Nov 2025
Q2 2025 $2.79M -$3.2M -53.4% 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 $2.79M -$3.2M -53.4% 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $2.79M -$3.2M -53.4% 31 Dec 2024 10-Q 17 Nov 2025
Q3 2024 $2.79M -$3.2M -53.4% 30 Sep 2024 10-Q 19 Nov 2024
Q2 2024 $5.99M $0 0% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $5.99M -$6.08M -50.4% 31 Mar 2024 10-Q 15 May 2024
Q4 2023 $5.99M -$6.08M -50.4% 31 Dec 2023 10-Q 17 Nov 2025
Q3 2023 $5.99M -$10.2M -63% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $5.99M -$10.2M -63% 30 Jun 2023 10-Q 18 Aug 2023
Q1 2023 $12.1M -$8.99M -42.7% 31 Mar 2023 10-Q 22 May 2023
Q4 2022 $12.1M -$8.99M -42.7% 31 Dec 2022 10-K 15 Apr 2025
Q3 2022 $16.2M -$4.88M -23.2% 30 Sep 2022 10-Q 18 Nov 2022
Q2 2022 $16.2M -$4.88M -23.2% 30 Jun 2022 10-Q 22 Aug 2022
Q1 2022 $21.1M +$2.00 0% 31 Mar 2022 10-Q 23 May 2022
Q4 2021 $21.1M $0 0% 31 Dec 2021 10-K 12 Apr 2024
Q3 2021 $21.1M $0 0% 30 Sep 2021 10-Q 22 Nov 2021
Q2 2021 $21.1M $0 0% 30 Jun 2021 10-Q 20 Aug 2021
Q1 2021 $21.1M -$2 0% 31 Mar 2021 10-Q 24 May 2021
Q4 2020 $21.1M $0 0% 31 Dec 2020 10-K/A 20 Apr 2023
Q3 2020 $21.1M +$16.3M +343% 30 Sep 2020 10-Q 16 Nov 2020
Q2 2020 $21.1M +$16.3M +343% 30 Jun 2020 10-Q 14 Aug 2020
Q1 2020 $21.1M +$16.2M +330% 31 Mar 2020 10-Q 29 Jun 2020
Q4 2019 $21.1M 31 Dec 2019 10-K 15 Apr 2021
Q3 2019 $4.75M 30 Sep 2019 10-Q 19 Nov 2019
Q2 2019 $4.75M 30 Jun 2019 10-Q 19 Aug 2019
Q1 2019 $4.9M 30 Apr 2019 10-Q 14 Nov 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.